Compass Pathways: A Psychedelics Story
COMPASS Pathways is making progress with its psilocybin therapy, COMP360, aimed at treating treatment-resistant depression (TRD). The company plans to submit a rolling New Drug Application (NDA) by the fourth quarter of 2026. Recent Phase 3 trials have shown promising results in terms of efficacy and safety.
- ▪COMPASS Pathways is advancing its psilocybin therapy, COMP360, for treatment-resistant depression.
- ▪A rolling New Drug Application submission is expected by the fourth quarter of 2026.
- ▪COMP360 has shown statistically significant efficacy and safety in two pivotal Phase 3 trials.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4909974-compass-pathways-a-psychedelics-story"},"author":{"@type":"Person","name":"Busted IPO Forum","url":"https://seekingalpha.com/author/busted-ipo-forum"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
